22/07/2015 : Theradiag signs collaboration agreements with Unicancer and Bordeaux University Hospital to advance microRNA project in rectal cancer

Theradiag reaches new milestone in the development of two new theranostics tests in rectal cancerTheradiag secures access to multicentric patient cohorts with two leading cancer research partnersCroissy-Beaubourg and Montpellier, July 22, 2015 – Theradiag (ISIN:…

Continue Reading 22/07/2015 : Theradiag signs collaboration agreements with Unicancer and Bordeaux University Hospital to advance microRNA project in rectal cancer

17/07/2015 : New study shows predictive role of theranostics in Inflammatory Bowel Disease

Further validation of routine biotherapy monitoring in IBD patientsUndetectable anti-TNF drug levels in IBD patients with long-term remission predicts relapse-free survival after drug withdrawal  Croissy-Beaubourg and Montpellier, June 17, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER),…

Continue Reading 17/07/2015 : New study shows predictive role of theranostics in Inflammatory Bowel Disease

26/05/2015 : THERADIAG RECEIVES FROST & SULLIVAN 2015 EUROPEAN THERANOSTICS PRODUCT LEADERSHIP AWARD

Croissy-Beaubourg and Montpellier, May 26, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that is has been awarded  the Frost & Sullivan 2015 European Theranostics Product…

Continue Reading 26/05/2015 : THERADIAG RECEIVES FROST & SULLIVAN 2015 EUROPEAN THERANOSTICS PRODUCT LEADERSHIP AWARD